ArticleNature nanotechnology2024
Age-associated disparity in phagocytic clearance affects the efficacy of cancer nanotherapeutics.
Article in Nature nanotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Shared and niche-specific transcriptional signatures of macrophage aging revealed by a cross-tissue meta-analysis.BMC biology · 2026Pooled it
- Nanoparticles based on photothermal effects in the treatment of hepatocellular carcinoma (HCC): a meta-analysis and systematic review.BMC cancer · 2026Pooled it
- Nanomedicine beyond carriers - devices, cells & living therapeutics.Biomedical microdevices · 2026Review
- A transferable gut microbiota-bile acid pathway programs nanomedicine pharmacokinetics and therapeutic response.Nature materials · 2026Article
- Ultrasound-responsive nanodroplets activate the Hippo pathway via ROS-MST1-YAP cascade for breast cancer therapy.Ultrasonics sonochemistry · 2026Article
- Engineering challenges and translational opportunities in emerging gene delivery platforms.Nature biomedical engineering · 2026Review
- Global trends and projections of lung cancer attributable to residential radon exposure, 1990-2050.BMC cancer · 2026Article
- Poor prognosis outcome tumors, bacteria-infected tumors and nanodrugs: current evidence and hypotheses towards a paradigm change for treatment.Cancer biology & medicine · 2026Review
- Rational design of rigid mRNA folding architecture to enhance intracellular processing and protein production.Nature nanotechnology · 2026Article
- Ultrasound-Boosted Liposomal Prodrug Overcomes Age-Associated Biodistribution Disparity in Pediatric Solid Tumor Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Of Barriers and Loops-How Evolution Limits Most Cancer Risks to Older Ages.Cancer discovery · 2026Review
- Distinct macrophage uptake of engineered and biological particles driven by host age and sex.Science and technology of advanced materials · 2026Article
- Biomimetic nanovaccines in cancer therapy: mechanisms, efficacy, and clinical translation.Materials today. Bio · 2025Review
- Chinese herbal medicine on the offspring of women with polycystic ovary syndrome: A retrospective cohort study.Medicine · 2025Article
- Obesity enhances ovarian cancer chemotherapy efficacy through C1q-mediated tumor targeting and immune activation.Journal of nanobiotechnology · 2025Article
- Nanotechnology for immuno-oncology.Nature cancer · 2025Review
- Advances in medical devices using nanomaterials and nanotechnology: Innovation and regulatory science.Bioactive materials · 2025Review
- Exosomes: a double-edged sword in cancer immunotherapy.MedComm · 2025Review
- Exploring the role of LOX family in glioma progression and immune modulation.Frontiers in immunology · 2025Article
- Learning what keeps nanomedicines in tumours.Nature biomedical engineering · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 4 institutions in 2 countries.
Funding
Abstract
Nanomedicines have been approved to treat multiple human diseases. However, clinical adoption of nanoformulated agents is often hindered by concerns about hepatic uptake and clearance, a process that is not fully understood. Here we show that the antitumour efficacy of cancer nanomedicine exhibits an age-associated disparity. Tumour delivery and treatment outcomes are superior in old versus young mice, probably due to an age-related decline in the ability of hepatic phagocytes to take up and remove nanoparticles. Transcriptomic- and protein-level analysis at the single-cell and bulk levels reveals an age-associated decrease in the numbers of hepatic macrophages that express the scavenger receptor MARCO in mice, non-human primates and humans. Therapeutic blockade of MARCO is shown to decrease the phagocytic uptake of nanoparticles and improve the antitumour effect of clinically approved cancer nanotherapeutics in young but not aged mice. Together, these results reveal an age-associated disparity in the phagocytic clearance of nanotherapeutics that affects their antitumour response, thus providing a strong rationale for an age-appropriate approach to cancer nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.